Nevro Corp. (NYSE:NVRO) Shares Purchased by BNP Paribas Financial Markets

BNP Paribas Financial Markets raised its stake in Nevro Corp. (NYSE:NVRO) by 171.3% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 135,145 shares of the medical equipment provider’s stock after purchasing an additional 85,324 shares during the quarter. BNP Paribas Financial Markets’ holdings in Nevro were worth $755,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in the company. Quantbot Technologies LP increased its stake in Nevro by 1,290.4% during the third quarter. Quantbot Technologies LP now owns 14,418 shares of the medical equipment provider’s stock worth $81,000 after acquiring an additional 13,381 shares during the last quarter. Charles Schwab Investment Management Inc. increased its position in Nevro by 3.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 303,675 shares of the medical equipment provider’s stock worth $1,698,000 after purchasing an additional 11,369 shares in the last quarter. Intech Investment Management LLC purchased a new position in Nevro in the third quarter valued at approximately $69,000. Assenagon Asset Management S.A. lifted its position in Nevro by 27.6% during the third quarter. Assenagon Asset Management S.A. now owns 929,348 shares of the medical equipment provider’s stock valued at $5,195,000 after buying an additional 200,885 shares in the last quarter. Finally, SG Americas Securities LLC purchased a new stake in Nevro during the third quarter worth approximately $71,000. 95.52% of the stock is owned by hedge funds and other institutional investors.

Nevro Trading Down 0.7 %

NYSE NVRO opened at $4.31 on Thursday. The company has a market capitalization of $161.50 million, a price-to-earnings ratio of -2.28 and a beta of 0.84. The company has a debt-to-equity ratio of 0.67, a current ratio of 5.02 and a quick ratio of 3.76. Nevro Corp. has a 12 month low of $3.95 and a 12 month high of $22.64. The company’s fifty day moving average price is $4.78 and its two-hundred day moving average price is $6.55.

Nevro (NYSE:NVRO) last announced its quarterly earnings data on Monday, November 11th. The medical equipment provider reported ($0.41) earnings per share for the quarter, beating the consensus estimate of ($0.81) by $0.40. Nevro had a negative return on equity of 23.52% and a negative net margin of 16.54%. The firm had revenue of $96.60 million during the quarter, compared to analyst estimates of $93.09 million. During the same period in the previous year, the company earned ($0.65) earnings per share. Nevro’s quarterly revenue was down 7.0% on a year-over-year basis. As a group, research analysts predict that Nevro Corp. will post -2.43 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

NVRO has been the topic of a number of research reports. JMP Securities reissued a “market perform” rating on shares of Nevro in a research note on Tuesday, November 12th. Canaccord Genuity Group reduced their price objective on Nevro from $7.00 to $4.00 and set a “hold” rating on the stock in a research note on Monday. Royal Bank of Canada reiterated a “sector perform” rating and issued a $7.00 target price on shares of Nevro in a research note on Tuesday, November 12th. StockNews.com raised Nevro from a “sell” rating to a “hold” rating in a research report on Tuesday, November 19th. Finally, Piper Sandler lowered their price objective on shares of Nevro from $7.00 to $6.00 and set an “underweight” rating for the company in a research report on Tuesday, November 12th. Three equities research analysts have rated the stock with a sell rating and twelve have issued a hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $8.05.

About Nevro

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems.